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Posaconazole is indicated for prophylaxis and treatment of invasive aspergillosis. 
Therapeutic drug monitoring (TDM) of posaconazole is used to optimize drug exposure. The 
aim of this study was to analyse and describe the TDM practices and exposure of 
posaconazole tablets.  
 
Materials/methods: 
Patients who received posaconazole for treatment or prophylaxis of fungal infections were 
included in the study. The following therapeutic window was defined: if concentration was 
low (<0.7mg/L for prophylaxis or <1.5 mg/L for treatment) or high (>3.75mg/L) the hospital 
pharmacist provided the physician with dosage advice, which implementation to patient 
care was analysed. A longitudinal analysis was performed to analyse if different confounding 
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Results: 
Forty-seven patients were enrolled resulting in 217 posaconazole trough concentrations. A 
median of 3 (IQR 1-7) samples were measured per patient. The median concentration was 
1.7 mg/L (IQR 0.8-2.7) for prophylaxis and 1.76 mg/L (IQR 1.3-2.3) for treatment. Overall 78 
posaconazole concentrations were out of the therapeutic window. For 45 (54%) of these 
concentrations a dosage change was recommended. In 54 (25%) of all measured 
posaconazole concentrations resulted in recommendation for dosage alteration. In the 
longitudinal analysis the laboratory markers and patient baseline variables did not have an 
effect on posaconazole concentrations. 
 
Conclusions: 
Adequate posaconazole exposure was shown in in 64% (affected 28 patients) of the 
measured concentrations. TDM practice of posaconazole can be improved by increasing the 





Invasive fungal infections (IFIs) are still the most common infection-related causes for death 
among immunocompromised patients1,2. Haematopoietic stem cell transplant recipients 
(HSCT), solid organ transplant recipients and other immunocompromised patients are at risk 
for fungal infections1. According to most recent Infectious Diseases Society of America 
(IDSA) Aspergillosis and Candidemia guidelines, azoles (voriconazole, posaconazole, 
fluconazole, isavuconazole, itraconazole), liposomal Amphotericin B, micafungin, 
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Posaconazole is active against a wide spectrum of pathogens including Candida species, 
Aspergillus species and zygomycetes5. This has led to posaconazole being used for 
prophylaxis and treatment of fungal infections6–8. However, posaconazole plasma 
concentrations may be influenced by other medications and diet, especially when 
posaconazole suspension is used9–12. Additionally, related to the clinical condition of the 
patient, the physiological status of these patients can have an impact on pharmacokinetics 
of different drugs. For instance there can be a change in the volume of distribution during 
fluid therapy and metabolism or clearance of drugs during hepatic and renal function 
disorders13. A significant variation of posaconazole concentrations has been reported 
between and within patients9,10. 
 
Therapeutic drug monitoring (TDM) is recommended in guidelines for treatment 
optimization for posaconazole and other azoles like voriconazole and itraconazole2,3. TDM 
can be recommended based on an exposure response relationship14 and association of 
higher drug concentrations with better outcome in daily practice6,7,15. For posaconazole 
there is considered to be clinical benefit from TDM as posaconazole concentrations show 
large inter-and intra-patient variability, especially when the suspension is used9,16,17.  
 
In contrast to the suspension, currently used posaconazole tablets and intravenous infusion 
are expected to result in more stable posaconazole concentrations18,19. TDM of 
posaconazole has been performed for several years20–23, but the quality of TDM (application 
to clinical practice, dose alteration recommendations by pharmacists, optimal timing of 
measurements) and its implication to clinical practice has not been extensively addressed in 
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potential benefit of TDM in clinical practice for the newer drug formulations. Therefore, 
TDM of posaconazole has continued to be a subject of debate25,26. A recent study 
investigated the effect of inflammation reflected by C-reactive protein (CRP) on 
posaconazole metabolism27. It was concluded that CRP does not affect posaconazole 
exposure. However other laboratory markers may be associated with altered drug exposure. 
For instance, due to chemotherapy, concomitant medications can cause liver function 
disorders which affect the pharmacokinetic processes like absorption, distribution, 
elimination, metabolism, which can lead to changes in posaconazole exposure28. Analysing 
potential effect of routine laboratory markers can help defining the appropriate population 
for TDM of posaconazole. 
The aim of this study was to evaluate the TDM practice in haematologic patients of 
posaconazole after the introduction of the new drug formulations and give 
recommendations for improvement of routine clinical practices of TDM. Additionally, we 
analysed if the routine laboratory measurements have effect on posaconazole 
concentrations.  
 
Material and methods 
A post-hoc analysis was performed from a prospective observational study conducted 
between August 2015 and June 2017 in the University Medical Center Groningen (UMCG), 
the Netherlands27. Patients (aged ≥18 years) with haematological malignancies, who 
received intravenous and/or oral posaconazole for treatment, or (primary and secondary) 
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The study was reviewed by the local ethics committee and received approval (Institutional 
Review Board 2013-491). A written informed consent for collection of the medical data was 
obtained from each enrolled patient. 
 
For every patient, information about posaconazole administration was recorded and 
included: posaconazole dose, indication for posaconazole (treatment or prophylaxis), route 
of administration (oral or intravenous), time of administration, day after treatment initiation 
with posaconazole and posaconazole serum concentration. In addition we collected 
laboratory analysis C-reactive protein (CRP), alkaline phosphatase (ALP) , aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), γ-GT (gamma-glutamyltransferase) 
and bilirubin values. The blood samples for measuring posaconazole serum concentrations 
were collected for routine care and concentrations were measured using a validated liquid 
chromatography-tandem mass spectrometry assay29. In addition, other patient data 
including age, gender, height, underlying disease were collected.  
 
During daily treatment with posaconazole, dosages were increased if pre-dose trough 
concentrations were too low (i.e. < 0.7mg/L for prophylaxis or < 1.5 mg/L for treatment) or 
decreased if pre-dose trough concentrations were too high (>3.75 mg/L, both treatment and 
prophylaxis), however no upper toxicity-threshold for posaconazole levels is known15,30. For 
this study steady state was assumed on day 6 with a loading dose and on day 10 without a 
loading dose31. The concentrations obtained prior to steady state were not included in the 
longitudinal analysis. The samples that were not at steady state were used to analyse TDM 
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The recommendations including dosage advice given by the clinical pharmacist if the 
posaconazole concentrations was out of the therapeutic range were collected from the 
electronic prescribing and laboratory information systems. To determine intra-patient 
variability in posaconazole plasma concentrations, patients who had more than one trough 
concentration measured were included in this subgroup analysis. 
 
For the analysis of TDM practices it was documented if a recommendation was provided 
when posaconazole concentrations were out of the therapeutic window. Additionally, the 
overall number of recommendations provided and how many of these required a dosage 
change were summarized. When a recommendation to change the dose was followed by an 
actual dose change this was considered as a successful implementation into patient care.  
 
For patients who received posaconazole for prophylaxis, occurrence of a breakthrough 
invasive fungal infection was documented. For all patients (receiving posaconazole for 
prophylaxis and treatment) 28-day and 12-week overall survival was documented, to 
analyze short and long-term survival. It was taken into account that optimum IFI treatment 
duration is 6-12 weeks.32 
 
Numerical variables were summarized with medians and interquartile range, while 
categorical variables were summarized by frequencies and percentages. The longitudinal 
data on posaconazole concentration was analyzed with a random intercept model for 
subjects. For the longitudinal analysis we included only steady state concentrations as 
defined in our prospective study27. The baseline variables gender, age, route of 
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and CRP were included as independent variables. The Wald-type type 3 test statistic was 
applied to test for the null hypothesis (α = 0.05) that the independent variables do not 
contribute to the posaconazole concentration. Multiple imputation, using predictive mean 
matching on all variables in the mixed model and 20 imputation data sets, was applied as 
sensitivity analysis. Pooled estimates were obtained using Rubin’s rule. The analyses were 




Between August 2015 and June 2017, 47 patients with a median age of 62 (IQR 56-67) were 
enrolled in this study and 217 posaconazole samples were available for analysis for TDM 
practices and 182 samples for longitudinal analysis. Seven samples were excluded for 
further analysis as posaconazole was not detectable (<0.1 mg/L) because the drug was 
stopped before that time, and one sample for one patient because of missing start date.  
 
Most common underlying disease was acute myeloid leukemia (AML, 61%) and the majority 
of patients (70%) received posaconazole for prophylaxis. Posaconazole modified release 
(MR) tablets were the main drug formulation used (89%) and 5 patients (11%) had 
treatment with both intravenous infusion which was followed by MR tablet throughout the 
study. Almost half (49%; 23/47) of the patients received a loading dose of 300mg two times 
daily on the first day of treatment. The median daily dose for all measured concentrations 
was 4.1 mg/kg (IQR 3.5-6.1), 2 patients were on dose 200 mg/day (prophylaxis), 33 patients 
were on dose 300 mg/day (26 prophylaxis, 7 treatment), 1 patient was on dose 600 mg/day 
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treatment period. Other patient characteristics are described in Table 1. Figure 1 shows first 
and subsequent posaconazole concentrations.   
 
Analysis of TDM practices  
For 212 (98%) posaconazole concentrations a recommendation by a clinical pharmacist was 
given and made available to the physician in the electronic patient records. For 54 (25%) of 
these samples (31 prophylaxis, 23 curative treatment) a dosage change was recommended. 
However, dose recommendations were implemented in only 39% (10 prophylaxis, 11 
treatment) of the cases. For 6 samples we did not have follow-up dosing. 
 The other dosages that were not changed (n=27) can be explained by some suggestions 
given on a Friday or during weekend (n=5), borderline concentrations 0.5-0.7 mg/L for 
prophylaxis and 1.0-1.5 mg/L for treatment (n=8), concentrations over 3.75 mg/L as there is 
no upper toxicity concentration confirmed (n=7), concentrations measured before day 6, 
the assumed steady state (n=2) and other reasons (n=5).  
 
Prophylaxis with posaconazole 
Thirty-three patients received posaconazole for prophylaxis (126 posaconazole samples) and 
32 of them were on MR tablets only. A median of 2 (IQR 1-4) blood samples were taken per 
patient and the median drug concentration was 1.7 mg/L (IQR 0.8-2.7), the interpatient 
variance was 1.53 and standard deviation 1.24. Figure 2 shows intra- and interpatient 
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Overall 88 concentrations were within the therapeutic range (0.7 – 3.5 mg/L) and 32 outside 
(16 samples <0.7mg/L, 16 samples >3.75mg/L). Table 2 presents the samples outside the 
predefined therapeutic window and posaconazole therapy.   
 
From 33 patients who received posaconazole for prophylaxis, three patients (9%) developed 
a probable IFI and one (3%) received posaconazole as empiric treatment for IFI (suspected 
breakthrough IFI). These patients had adequate posaconazole concentrations – all samples 
measured were over 0.7 mg/L. The detailed description of these patients are presented in 
Table 3.  
 
The mortality rate in the total prophylaxis group was 6% (2 patients) after 28 days and 24% 
(8 patients) after 12 weeks. For the 2 patients who died after 28 days adequate 
posaconazole concentrations (≥0.7 mg/L) were observed. For the 8 patients who died after 
12 weeks, 6 had adequate posaconazole concentrations (≥0.7 mg/L) and 2 patients both had 
1 sample measured below 0.7 mg/L. Mortality was not attributed to a fungal infection. 
 
Treatment with posaconazole 
Fourteen patients received posaconazole MR tablets for treatment (91 posaconazole 
samples) and 4 received both posaconazole MR tablet followed by intravenous infusion or 
vice versa during the same treatment period.  A median of 6 (IQR 3-9) samples were taken 
per patient and the median drug concentration was 1.76 mg/L (IQR 1.3-2.3), the interpatient 
variance was 0.5 and standard deviation 0.71. Figure 2 shows intra- and interpatient 
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Forty-four posaconazole concentrations were within the therapeutic range (1.5 – 3.75 mg/L) 
and 46 outside (35 samples <1,5mg/L, 11 samples >3,75mg/L). Table 2 presents the samples 
outside the predefined therapeutic window and posaconazole therapy.   
 
The mortality rate in this group was 14% (2 patients) after 28 days and 29% (4 patients) 
after 12 weeks. For the 2 patients who died after 28 days adequate posaconazole 
concentrations (≥1.5 mg/L) were observed. For the 4 patients who died after 12 weeks 2 
had adequate posaconazole concentrations (≥1.5 mg/L) and 2 had some concentrations 
under the predefined therapeutic concentration (≤1.5 mg/L).  
 
Longitudinal analysis  
The associations of the independent variables on posaconazole concentration together with 
their 95% confidence interval and the Wald-type p-value are provided in Table 4. The results 
on the original data (with missing data) as well as the pooled estimates from the imputation 
are given. The original data set contains 127 measurements (from the 182 measurements) 
with a complete data set. 
 
It is obvious that the dose contributed to the posaconazole concentration. In the analysis of 
the original data set (with missing data), ALT seemed to contribute to the posaconazole 
concentration, but this association seemed to disappear when multiple imputation is being 
used. Multiple imputation showed that subjects who had missing data on ALT had on 
average a lower ALT value that the subjects from whom we observed ALT data (34.0 versus 
51.6). This may suggest that the associations of the independent variables in the original 
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Discussion 
The objective of this study was to analyze routine TDM practices of posaconazole. Our study 
showed that variability in drug exposure is still present. Posaconazole concentrations might 
be affected by treatment setting - some patients were treated in an outpatient setting. 
However, some of these patients suffered from graft-versus-host-disease, which can 
compromise the absorption of posaconazole33. Variability of posaconazole Cmin (MR tablet) 
was also described in a recent study on lung transplant recipients 34. However, we did see an 
increase of median posaconazole concentrations compared to a previous study done in our 
center with posaconazole suspension. In that study the median posaconazole concentration 
was 0.9 mg/L, in our study it was 1.7 mg/L (prophylaxis) and 1.76 mg/L (treatment). For 
most patients in van Elst et al study the patients received mostly 600 mg/day (84%) for 
prophylaxis and 800 mg/day (80%) for treatment. In this study 50% of the treatment group 
and 79% of the prophylaxis group received 300 mg of posaconazole per day9. So we did see 
a better exposure with posaconazole tablet and intravenous formulation compared with the 
suspension. Lenczuk and colleagues also have shown that posaconazole concentrations are 
more likely to be in the therapeutic range when patients are being treated with 
posaconazole modified release tablet35.  
 
Posaconazole concentrations have also been described to be affected by diarrhea, body 
weight, male gender, use of PPIs and steroids36,37. Our longitudinal analysis did not confirm 
the effect of weight and gender on posaconazole concentrations. We also did not see a 
change of AST levels, although posaconazole treatment is connected with liver function 
abnormalities38. On the other hand, it has also been presented previously that liver function 
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concentrations38. A limitation of our analysis is the fact that we did not analyse the effect of 
diarrhea and use of PPIs and steroids and that we included patients of a previous study, 
which is a part of all measured posaconazole concentrations during the study period thus 
does not represent the whole patient population. On the other hand, the characteristics of 
our dataset are somewhat similar to other studies describing posaconazole exposure in 
patients with haematological malignancies37,38. The novelty of our study compared to earlier 
studies is the longitudinal analysis, which is taking into account the day of treatment and the 
time between measurements, also including all samples that have been collected for each 
patient35–37. The advantage of using longitudinal analysis over univariate and multivariate 
analysis that have been used by earlier studies is that this type of analysis better values the 
effect of measurements over time.    
 
We cannot see a relationship between low posaconazole concentrations and mortality 
rates. Additionally, this dataset is too small to show that low concentrations have an effect 
on outcomes, especially as we did not determine IFI-attributable deaths. For treatment of 
IFIs, higher posaconazole plasma concentrations must be obtained26. In this study, over half 
of the concentrations measured for IFI treatment were below the therapeutic range (<1.5 
mg/L). For patients receiving posaconazole as treatment significantly more samples were 
taken per patient compared with patients receiving posaconazole as prophylaxis. On the 
other hand, in this study, the defined therapeutic concentration (≥1.5 mg/L) used for 
treatment of IFIs was higher than previously reported (≥1 – 1.25 mg/L) to prevent antifungal 
resistance and to cover all strains15,26. This caused more posaconazole concentrations to be 
out of the therapeutic window. If the therapeutic concentration of ≥1 mg/L was used more 
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Our dataset is too small to draw firm conclusions, although, most patients receiving 
posaconazole as prophylaxis and who had a breakthrough infection, had a therapeutic 
posaconazole concentration. However, three patients who received posaconazole for 
treatment did not have sufficient drug concentrations even when a loading dose was 
administered. Perhaps administering a double dose for more than 1 day when posaconazole 
is used for treatment of IFIs should therefore be considered.   
 
A suggestion for dose alteration was only followed for 39% of recommendations made. The 
reasons behind non-implementation could have been due to borderline concentrations and 
samples over 3.75 mg/L as posaconazole toxic concentration has not been confirmed in 
literature nor by the manufacturer31. Posaconazole practices were analysed before in 
conjunction with effect of concomitant medications, diet, concomitant chemotherapy and 
other variables42. Additionally, in that study approximately for 20% of patients’ dosage 
changes were done, which led to more therapeutic concentrations. The benefit of TDM 
could was suggested due to also the varying posaconazole concentrations when using 
suspension, however not described in great detail. In this analysis we show that a quarter of 
posaconazole concentrations receive a suggestion for dosage change. Knowing that most of 
the patients received the oral formulation (tablet or suspension) we observed that TDM is 
still beneficial in this patient group.  The overall results of this study and specific cases 
should be discussed in a multidisciplinary expert panel to avoid unnecessary orders and 
improve overall TDM practices taking into account different reasons behind non-
impementation. Currently, the recommendations are documented into an electronic system 











This article is protected by copyright. All rights reserved. 
physicians and pharmacists, an attending clinical pharmacist may be necessary, who would 
provide face-to-face consultations, thus aiding in preventing medication related errors and 
reducing costs39–41.  
 
Furthermore, antimicrobial stewardship teams are widely initiated in hospitals worldwide 
and it has been suggested that these teams should also include a pharmacist39. The 
pharmacist could aid in choosing the best drug formulation to use, consult on appropriate 
empirical and prophylactic approaches, promote switching from intravenous to oral 
antimicrobials, analyze drug interactions and provide information about pharmacokinetics 
and TDM including prescribing of the new dose based on the TDM results43. Besides this, the 
team should be advising appropriate antimicrobial therapy taking the specific patient and 
condition, documenting and analyzing resistance patterns into account40,44.  
 
Conclusions 
Adequate posaconazole exposure was shown in in 64% (affected 28 patients) of the 
measured concentrations. There was still an important variability present in posaconazole 
exposure, however in the longitudinal analysis from all the confounders only dose had a 
significant effect on posaconazole concentrations.   
 
Even though posaconazole concentrations varied and recommendations were not always 
implemented to patient care, a large proportion of trough concentrations lied within the 
therapeutic range and did not need a recommendation at all. The communication between 
the clinical pharmacist and the attending physician should be enhanced to achieve better 
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Table 1. Patient characteristics (n=47) 
Characteristic No. (%) of patients or median (IQR)  
 Prophylaxis Treatment 
Gender   
  Male   17 (36)                         10 (21) 
Age (years) 62 (57-68) 60 (52-67) 
BMI (kg/m2) 24.5 (23.5-27.7) 24.4 (21.7-26.6) 
Underlying conditions   
    AML 19 (40) 11 (24) 
    MDS 7 (15) 1 (2) 
    Other* 7 (15) 2 (4) 
Stem cell transplantation    
    Allogeneic  14 (30) 5 (11) 
    Autologous 2 (4) 0 
    No transplantation 17 (36) 9 (19)  
 
Abbreviations: BMI – Body Mass Index, AML – acute myeloid leukemia, MDS – 
myelodysplastic syndrome 
*Other includes X-linked gammaglubulinemia, T-cell prolymphocytic leukemia, follicular 
lymphoma, chronic myelomonocytic leukemia, Burkitt’s lymphoma, blastic plasmacytoid 
dendritic cell neoplasm, enteropathy associated T-cell lymphoma type 2, systemic 
mastocytosis, primary cutaneous T-cell lymphoma, aplastic anemia, primary myelofibrosis 
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Table 2. Posaconazole concentrations during prophylaxis and treatment 
 33 (%) patients on 
prophylaxis 
14 (%) patients on  
treatment  
    Route of administration   
        Oral  32 (68) 11 (24) 
        Intravenous and oral 1 (2) 3 (6) 
    Loading dose  17 (36) 6 (13) 
    Daily dose (mg/kg) 3.5 (3.4-4.3) 5.3 (4.2-6.8) 
        Number of samples taken 
per patient     
2 (1-3.5) 5.5 (2.75-9) 
Number of Posaconazole samples  120  concentrations obtained 
for prophylaxis 
90 concentrations obtained for 
treatment 
Posaconazole <0.7 mg/L   16 (# of samples)  
Posaconazole <1.0 mg/L  14 (# of samples) 
Posaconazole <1.5 mg/L  35 (# of samples) 
Posaconazole >3.75 mg/L 16 (# of samples) 11 (# of samples) 
Posaconazole <0.7 mg/L with 
loading dose after/on day 6 / 
without loading dose after/on 
day 10  
10  / 4 (# of samples)  
Posaconazole <1.5 mg/L with 
loading dose after/on day 6 / 
without loading dose after/on 
day 10  
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Table 3. Clinical data of the patients who got a probable or possible breakthrough infection 









 IFI treatment Chemotherapy/ 
antimicrobial 
therapy 
Diagnosis of IFI 
1  59-year-old woman 
with AML and had 
received a SCT 












changes in the scan,  
galactomannan 
antigene serum index: 
0.56, galactomannan 
antigene BAL index 
0.35  
2  46-year-old man 
with AML  
1.26 mg/L 2.6 mg/L,  
3.2 mg/L 
 Amphotericin 









HRCT: positive masses 
in liver, 
galactomannan 







had received a SCT 











antigene BAL index 
4.90 
 
Abbreviations: NI – no information  
 
 
Table 4. Results of longitudinal analysis  
Variable Original data set Imputed data sets 
 Estimate [95%CI] p-value Estimate [95%CI] p-value 
 -0.172 [-1.341; 0.996] 0.766 0.258 [-0.570; 1.084] 0.542 
Age 0.032 [-0.020; 0.084] 0.213 0.021 [-0.016; 0.058] 0.258 
Route of 
administration 
0.322 [-0.848; 1.492] 0.587 0.230 [-0.769; 1.229] 0.652 
Dose 0.387 [0.247; 0.527] <0.001 0.296 [0.167; 0.425]  <0.001 
ALT 0.006 [0.000; 0.012] 0.040 0.004 [-0.003; 0.010] 0.266 
AST 0.004 [-0.013; 0.021] 0.648 0.005 [-0.013; 0.023] 0.575 
ALP -0.001 [-0.008; 0.007] 0.870 0.001 [-0.006; 0.007] 0.815 
γ-GT -0.000 [-0.003; 0.003] 0.939 -0.000 [-0.003; 0.002] 0.803 
Bilirubin -0.009 [-0.035; 0.016] 0.467 -0.006 [-0.025; 0.012] 0.506 














This article is protected by copyright. All rights reserved. 
Figure 1. The distribution of initial posaconazole trough concentrations (n=47 panel A) and 
the distribution of subsequent posaconazole trough concentrations (n=170 panel B).  
Figure 2. Intra-and interpatient variability of posaconazole concentrations in prophylaxis (A) 
and treatment (B) groups, x-axis presents patient number with the daily dose (mg/kg), y-axis 
presents number of samples   
 
 
 
 
 
 
 
 
